BackgroundGallbladder cancer (GBC) is a mortal malignancy with limited therapeutic strategies. We aimed to develop novel immune scoring systems focusing on B7-H3. B7-H4. and HHLA2. https://www.marcelovicente.com/product-category/60-sec-treatment/